Charterhouse Capital Partners agreed on 16 April to acquire Animalcare Group, the York-based veterinary pharmaceuticals sales and marketing company listed on AIM, in a recommended cash deal valuing it at about £235.2m.
Deal terms and financing
Bidco CCP Paw 2 offered 336p in cash per share. Eligible shareholders could instead take unlisted aggregator interests in the bidding group for at least 66% of their shares. The directors irrevocably undertook to vote 16.1m shares, about 23.3% of the capital, in favour.
Regulatory approvals and timing
Shareholders voted on the scheme at court and general meetings on 8 June 2026, and the Australian Foreign Investment Review Board condition was later satisfied. The High Court sanctioned the scheme on 28 July and it became effective on 30 July 2026; Animalcare's admission to AIM was cancelled on 31 July.
Market context
Animalcare is an international veterinary sales and marketing organisation headquartered in York. Charterhouse is a London-based mid-market private equity firm.
